Back to results
US 9,809,858 B2Granted
O-glycan pathway ovarian cancer signature
AssigneeH. Lee Moffitt Cancer Center and Research Institute, Inc.
InventorsJohnathan M. Lancaster, Douglas C. Marchion, Yin Xiong
Life of this patent
Estimating the term…
Abstract
Biomarkers, methods, assays, and kits are provided for determining the prognosis of and treating a patient with ovarian cancer. Also disclosed are biomarkers, methods, assays, and kits for predicting the sensitivity of ovarian cancer cells to chemotherapy.
Claims9
A method for determining the prognosis of a patient with ovarian cancer, comprising
- a) assaying a biological sample from the subject for the expression level of at least ten (10) O-glycan biosynthesis pathway (OGBP) genes selected from the group consisting of B3GALT1, B3GALT2, B3GALT4, B3GALT5, B3GNT6, B4GALT1, B4GALT2, B4GALT3, C1GALT1, GALNT1, GALNT10, GALNT11, GALNT12, GALNT13, GALNT14, GALNT2, GALNT3, GALNT4, GALNT5, GALNT6, GALNT7, GALNT8, GALNT9, GALNTL1, GALNTL2, GALNTL4, GALNTL5, GCNT1, GCNT2, GCNT3, ST3GAL1, ST3GAL2, ST6GALN, and WBSCR17;
- b) comparing the expression levels of the genes to control values to produce a gene profile;
- and
- c) analyzing the gene profile to calculate an OGBP risk score using standard statistical analysis, and
- d) optimally debulking the ovarian cancer if the patient has a high OGBP score, and not debulking or only suboptimally debulking the ovarian cancer if the patient has a low OGBP score.
2 more elements
Dependencies are inferred from the claim text.